Compare Citius Pharmaceuticals Inc (CTXR) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Teladoc Health Inc trades at $9.8 (market cap $1.67B). The key difference: Teladoc Health Inc is far larger — about 114.1× Citius Pharmaceuticals Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TDOC | |
|---|---|---|
Market Cap | $14.64M | $1.67B |
Sector | Health | Health |
52-Week High | $1.82 | $9.65 |
52-Week Low | $0.53 | $4.47 |
Enterprise Value | $10.86M | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TDOC trades at $9.65, up 3.99% with bullish technical signals but mixed fundamentals. Revenue remains stable around $2.5B, yet net losses persist with a -6.81% margin. Analyst consensus is cautious with 64% hold ratings, though recent partnerships like Walmart's Better Care show growth potential. Cash flow trends indicate significant net outflows, raising liquidity concerns despite a solid gross margin of 69.29%.
Outlook hinges on cost management and partnership execution; risks include sustained losses and high debt. The stock offers speculative upside if profitability improves, but investor patience is required amid competitive pressures and volatile sentiment. Current price near resistance at $10 suggests limited near-term upside without positive earnings surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
